Press release
Diabetic Macular Edema Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Diabetic Macular Edema Clinical Trials
Key Takeaways from the Diabetic Macular Edema Pipeline Report
• Over 60+ Diabetic Macular Edema companies are evaluating 65+ Diabetic Macular Edema pipeline therapies in various stages of development, and their anticipated acceptance in the Diabetic Macular Edema market would significantly increase market revenue.
• The leading Diabetic Macular Edema companies working in the market include Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, Asclepi X Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.
• Promising Diabetic Macular Edema Pipeline Therapies in the various stages of development include MYL-1701P, Eylea, Dexamethasone ophthalmic suspension (OCS-01), REGN910-3, Intravitreal Aflibercept Injection (IAI), and others.
• April 2024: AbbVie- A Multi-country, Post Marketing Observational Study of DME Patients With Suboptimal Response to Anti-VEGF Who Are Initiated With Dexamethasone Intravitreal Implant (DEX-I).
• April 2024: Bayer announced a study of Phase 4 clinical trials for Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321). The main purpose of this study is to collect more data to learn how safe intravitreal aflibercept is in Indian people with DME. To see how safe intravitreal aflibercept is, the researchers will collect the information/data on the medical problems the participants may have during the study, and which may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AEs). AEs will be categorized according to relatedness, seriousness, discontinuation of therapy, action taken and outcome.
Request a sample and discover the recent breakthroughs happening in the Diabetic Macular Edema Pipeline landscape @ Diabetic Macular Edema Pipeline Outlook Report- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Diabetic Macular Edema pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Diabetic Macular Edema NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is an eye condition which can occur in people living with diabetes - both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye.
Find out more about Diabetic Macular Edema Therapeutics Assessment @ Diabetic Macular Edema Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diabetic Macular Edema Emerging Therapies Profile
• MYL-1701P: Mylan Pharmaceuticals
MYL-1701P (also referred to as M710, as part of a partnership with Momenta Pharmaceuticals) is perhaps the aflibercept biosimilar that is furthest along in the development process. It is currently the subject of a 324-patient phase III trial. Mylan is to handle development and commercialization.
• KSI-301: Kodiak sciences
KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform KSI-301 is designed to have extended ocular half-life, higher potency, and improved ocular tissue bioavailability. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their DME with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to halt and reverse DR progression with long-term efficacy that can reduce the risk of vision-threatening complications from DR. The Phase III GLEAM and GLIMMER studies are global, multi-center, randomized studies designed to evaluate the efficacy, durability and safety of KSI-301 in patients with treatment-naïve diabetic macular edema (DME).
• CT-P42: Celltrion
CT-P42, an aflibercept biosimilar referencing Regeneron's Eylea. The trial will enroll 300 patients with diabetic macular edema, and aims to compare CT-P42's efficacy, safety, pharmacokinetics, and immunogenicity against Eylea.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of diabetic macular edema (DME)
Diabetic Macular Edema Therapeutics Assessment
There are approx. 60+ key Diabetic Macular Edema companies which are developing the Diabetic Macular Edema therapies. The Diabetic Macular Edema companies which have their Diabetic macular edema drug candidates in the most advanced stage, i.e. Phase III include, Mylan Pharmaceuticals.
DelveInsight's Diabetic Macular Edema pipeline report covers around 65+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Diabetic macular edema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Diabetic Macular Edema Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Diabetic Macular Edema Pipeline Therapies @ Diabetic Macular Edema Clinical Trials Assessment-
Scope of the Diabetic Macular Edema Pipeline Report
• Coverage- Global
• Diabetic Macular Edema Companies- Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, Asclepi X Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.
• Diabetic Macular Edema Pipeline Therapies- MYL-1701P, Eylea, Dexamethasone ophthalmic suspension (OCS-01), REGN910-3, Intravitreal Aflibercept Injection (IAI), and others.
• Diabetic Macular Edema Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Diabetic Macular Edema Pipeline Companies and Therapies, click here @ Diabetic Macular Edema Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Diabetic macular edema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. MYL-1701P: Mylan Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Diabetic macular edema Key Companies
17. Diabetic macular edema Key Products
18. Diabetic macular edema- Unmet Needs
19. Diabetic macular edema- Market Drivers and Barriers
20. Diabetic macular edema- Future Perspectives and Conclusion
21. Diabetic macular edema Analyst Views
22. Diabetic macular edema Key Companies
23. Appendix
Got Queries? Find out the related information on Diabetic Macular Edema Mergers and acquisitions, Diabetic Macular Edema Licensing Activities @ Diabetic Macular Edema Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-pipeline-insight
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Acute Pancreatitis Market: https://www.delveinsight.com/infographics/acute-pancreatitis-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
• Endoscopy Fluid Management Systems Market: https://www.delveinsight.com/blog/endoscopy-fluid-management-systems-market
• Gout Market: https://www.delveinsight.com/report-store/gout-market
• Graves' Disease Market: https://www.delveinsight.com/report-store/graves-disease-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-epilepsy-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Prader-willi Syndrome Market: https://www.delveinsight.com/report-store/prader-willi-syndrome-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Acanthamoeba Keratitis Market: https://www.delveinsight.com/report-store/acanthamoeba-keratitis-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/cutaneous-squamous-cell-carcinoma-epidemiology-assessment
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Macular Edema Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3737660 • Views: …
More Releases from DelveInsight Business Research
Global Patient Engagement Solutions Market to reach USD 59,499.28 million by 203 …
According to DelveInsight's analysis, The growth of the patient engagement solutions market is primarily fueled by several major factors, including the increasing burden of chronic conditions such as diabetes and cardiovascular diseases, which require continuous patient involvement and monitoring. The industry is further propelled by the move toward patient-centric healthcare models, ongoing technological innovations, and the introduction of new digital tools and platforms. Moreover, supportive government policies and initiatives aimed…
Global Magnetic Resonance Imaging Devices Market to reach USD 13,553.33 million …
According to DelveInsight's analysis, The growing incidence of chronic illnesses-including heart disease, cancer, and neurological disorders is driving demand for advanced diagnostic methods such as MRI, which provides highly detailed imaging of soft tissues and internal organs. Increasing awareness and a stronger focus on early disease detection are also prompting both patients and healthcare professionals to rely on MRI for faster and more accurate diagnosis. In addition, ongoing technological progress…
Global Microbial Fermentation Technology Market Size was USD 33,956.10 million i …
According to DelveInsight's analysis, The microbial fermentation technology market is experiencing strong growth, largely due to the increasing incidence of chronic illnesses such as cancer and a range of infectious diseases, including HIV, hepatitis B and C, and influenza. The market is also being boosted by the rising need for advanced therapeutic products like cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies. Moreover, progress in synthetic biology and precision…
Global Surgical Robotic System Market to reach USD 29,785.13 million by 2032 at …
According to DelveInsight's analysis, The growing prevalence of chronic illnesses such as cancer, cardiovascular diseases, and orthopedic disorders is driving demand for advanced surgical solutions, which in turn is accelerating the expansion of the surgical robotic systems market. Since many of these conditions require complex, highly precise procedures, robotic-assisted surgery is becoming a preferred option due to its superior precision, less invasive nature, and faster patient recovery. At the same…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
